



CORRECTION

Correction to: Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)

A. Pinter · A. Costanzo · S. Khattri · S. D. Smith · J. M. Carrascosa ·
Y. Tada · E. Riedl · A. Reich · A. Brnabic · N. Hastrup ·
A. Lampropoulou · I. Lipkovich · Z. Kadziola · C. Paul ·
C. Schuster

Published online: May 30, 2024
© The Author(s) 2024

Correction to: Dermatol Ther (Heidelb) <https://doi.org/10.1007/s13555-023-01086-9>

The authors would like to share the following corrections to their publication:

The email address of the corresponding author was updated to “andreas.pinter@pinter-med.com”.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s13555-024-01105-3>.

The original article can be found online at <https://doi.org/10.1007/s13555-023-01086-9>.

A. Pinter (✉)
University Hospital Frankfurt, Frankfurt am Main,
Germany
e-mail: andreas.pinter@pinter-med.com

A. Costanzo
Division of Dermatology, Humanitas Research
Hospital, Pieve Emanuele, Milan, Italy

A. Costanzo
Dermatology IRCCS Humanitas Research Hospital,
Rozzano, Milan, Italy

S. Khattri
Icahn School of Medicine at Mount Sinai, New York,
NY, USA

S. D. Smith
ANU Medical School, ANU College of Health and
Medicine, The Australian National University,
Canberra, Australia

On page 1, the words ‘Clinicaltrial.gov identifier’ were removed.

In the Introduction, the word ‘prospective’ was added to describe PSoHO.

In relation to super responders, the word ‘weight’ was removed and the incorrect citations of 13–15 were corrected.

Mastorino L, Susca S, Cariti C, et al. “Super-

J. M. Carrascosa
Department of Dermatology, Hospital Universitari
Germans Trias i Pujol, Universitat Autònoma of
Barcelona, IGTP, Carretera de Canyet, S/N, 08916
Badalona, Barcelona, Spain

Y. Tada
Department of Dermatology, Teikyo University
School of Medicine, Tokyo, Japan

E. Riedl · C. Schuster
Department of Dermatology, Medical University of
Vienna, Vienna, Austria

A. Reich
Department of Dermatology, Institute of Medical
Sciences, Medical College of Rzeszow University,
Rzeszow, Poland

A. Brnabic · N. Hastrup · A. Lampropoulou ·
I. Lipkovich · Z. Kadziola · C. Schuster
Eli Lilly and Company, Indianapolis, USA

C. Paul
Université Paul Sabatier Toulouse III, Toulouse,
France

responders” at biologic treatment for psoriasis: a comparative study among IL17 and IL23 inhibitors. *Exp Dermatol*. 2022;32:2187–8.

Ruiz-Villaverde R, Vasquez-Chinchay F, Rodriguez-Fernandez-Freire L, et al. Super-responders in moderate–severe psoriasis under guselkumab treatment: myths, realities and future perspectives. *Life*. 2022;12:1412.

Schäkel K, Reich K, Asadullah K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. *J Eur Acad Dermatol Venereol*. 37(10):2016–27.

The layout of Table 1 was updated for clarity and the statistical appendix is now provided.

Outcomes	Definition
Effectiveness	
Primary outcome	Patients who achieved (a) At least a 90% improvement in the PASI score (PASI90), or (b) A score of 0 or 1 in sPGA, or (c) Both outcomes
PASI100	Patients who achieved 100% improvement in the PASI score
PASI90	Patients who achieved at least a 90% improvement in the PASI score
Quality of life	
DLQI (0,1)	Patients with an available DLQI score of 2 or greater at baseline and who subsequently achieved a DLQI score of 0 or 1

Outcomes	Definition
Durability of effectiveness	
Durability of effectiveness outcome	Patients who met the primary outcome at week 12 and who subsequently at months 6 and 12 achieved an improvement of (a) At least a 75% in PASI score (PASI75), or (b) 2 or more points in sPGA score from baseline, or (c) Both outcomes
PASI100 durability outcome	Patients who achieved PASI100 at week 12 and then maintained PASI100 at both months 6 and 12
PASI90 durability outcome	Patients who achieved PASI90 at week 12 and then maintained at least PASI90 at both months 6 and 12

The original article has been corrected.

Open Access. This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.